106 withdrawn. 106 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 106 | Withdrawn 106 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-antibiotic Management in Acute Uncomplicated Diverticulitis Symptomatic treatment (ibuprofen and acetaminophen), Amoxicillin-clavulanate, Ciprofloxacin plus metronidazole - Acute Uncomplicated Diverticulitis | Phase 4 | Withdrawn | Montefiore Medical Center | 2026-07-01 | 2026-08-31 | |
| Effect of Sevoflurane and Desflurane on Heme Oxygenase-1 Expression in Elective Cholecystectomy Sevoflurane Group, Desflurane Group - Cholecystitis, Chronic | Phase 4 | Withdrawn | Kocaeli City Hospital | 2025-06-01 | 2025-02-05 | |
| Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications Adjuvanted Recombinant Zoster Vaccine (RZV) - Inflammatory Bowel Diseases, IBD | Phase 4 | Withdrawn | University of Wisconsin, Madison | 2024-10-01 | 2024-09-25 | |
| Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study Ozanimod Oral Capsule - Ulcerative Colitis | Phase 4 | Withdrawn | Geert D'Haens | 2024-08-01 | 2024-09-19 | |
| A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema RYMPHYSIA, Another Available A1PI - Chronic Obstructive Pulmonary Disease (COPD), Alpha1-Antitrypsin Deficiency | Phase 4 | Withdrawn | Takeda | 2024-01-01 | 2023-05-06 | |
| A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis Ketorolac, Placebo - Pancreatitis | Phase 4 | Withdrawn | University of California, San Francisco | 2023-11-01 | 2022-04-28 | |
| Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients Infliximab, Exclusive Enteral Nutrition - Crohn's Disease, Exclusive Enteral Nutrition | Phase 4 | Withdrawn | Children's Hospital of Fudan University | 2022-10-01 | 2022-08-09 | |
| Bezlotoxumab Versus FMT for Multiple Recurrent CDI Bezlotoxumab, Fecal Microbiota Transplantation (FMT), Vancomycin oral - Clostridium Infections, Clostridioides Difficile | Phase 4 | Withdrawn | Leiden University Medical Center | 2022-01-01 | 2023-03-28 | |
| A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients Indocyanine green - Gastric Cancer | Phase 4 | Withdrawn | Mayo Clinic | 2022-01-01 | 2023-07-19 | |
| Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) Glecaprevir/pibrentasvir - HCV Infection | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2021-10-01 | 2021-05-06 | |
| ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study ARALAST NP - Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 4 | Withdrawn | Shire | 2021-03-08 | 2020-09-14 | |
| Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis Rifampin - Cystic Fibrosis, MRSA | Phase 4 | Withdrawn | Johns Hopkins University | 2020-12-01 | 2021-01-14 | |
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c | Phase 4 | Withdrawn | Massachusetts General Hospital | 2020-11-13 | 2022-03-08 | |
| HCV + to HCV - Kidney Transplant Direct Acting Antivirals - Kidney Failure, Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2020-05-21 | 2022-08-31 | |
| Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer CREON - Exocrine Pancreatic Insufficiency (EPI) | Phase 4 | Withdrawn | AbbVie | 2020-05-06 | 2021-11-08 | |
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients Ultrasound Elastography, Contrast Enhanced Ultrasound (CEUS) - Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic | Phase 4 | Withdrawn | Children's Mercy Hospital Kansas City | 2020-04-01 | 2020-01-13 | |
| Barretts oEsophageal Resection With Steroid Therapy Trial Prednisolone, Placebo Oral Tablet - Barrett Esophagus, Esophageal Stenosis | Phase 4 | Withdrawn | Professor Michael Bourke | 2020-03-09 | 2025-03-27 | |
| Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] - Hepatitis C Virus Infection, Response to Therapy of | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2019-12-01 | 2020-04-20 | |
| Silymarin in NAFLD Silymarin, Placebo Oral Capsule - Non-Alcoholic Fatty Liver Disease | Phase 4 | Withdrawn | University Hospital Rijeka | 2019-09-20 | 2020-11-05 | |
| HCV Post-Exposure Prophylaxis for Health Care Workers Sofosbuvir/Velpatasvir Treatment for 14 days - Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-08-13 | 2020-01-21 |
Showing 20 of 106. Sign in to see all of them.
Hepatitis C (20) · Crohn Disease (9) · Gastroesophageal Reflux (9) · Colitis, Ulcerative (6) · Hepatitis B, Chronic (5) · Hepatitis C, Chronic (5) · Hepatitis B (4) · Liver Neoplasms (4) · Peptic Ulcer (4) · Renal Insufficiency (4) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Hepatitis A (3) · Inflammatory Bowel Diseases (3) · Laryngopharyngeal Reflux (3)
Gastrointestinal Diseases (50) · Liver Diseases (46) · Infections (35) · Intestinal Diseases (34) · Hepatitis, Viral, Human (32) · Pathological Conditions, Signs and Symptoms (32) · Virus Diseases (32) · Hepatitis (31) · Blood-Borne Infections (30) · Communicable Diseases (30) · Pathologic Processes (26) · RNA Virus Infections (25) · Flaviviridae Infections (22) · Gastroenteritis (18)
elbasvir-grazoprevir drug combination (6) · Omeprazole (5) · Sofosbuvir (5) · Lansoprazole (4) · Pantoprazole (4) · Ribavirin (4) · Esomeprazole (3) · Metronidazole (3) · Telbivudine (3) · glecaprevir and pibrentasvir (3) · vedolizumab (3) · Acetaminophen (2) · Adalimumab (2) · Blood Specimen Collection (2) · Ciprofloxacin (2)
Massachusetts General Hospital (5) · Mayo Clinic (4) · GlaxoSmithKline (3) · Merck Sharp & Dohme LLC (3) · Montefiore Medical Center (2) · Raymond T. Chung, MD (2) · Takeda (2) · Temple University (2) · University of California, San Francisco (2) · University of Maryland, Baltimore (2) · Xijing Hospital of Digestive Diseases (2) · AbbVie (1) · Abbott (1) · Ahmed Nasr (1) · Albert Einstein Healthcare Network (1)
United States (42) · Canada (7) · United Kingdom (4) · Germany (3) · Japan (3) · Australia (2) · China (2) · Israel (2) · Switzerland (2) · Turkey (Türkiye) (2) · Belgium (1) · Croatia (1) · Czechia (1) · Egypt (1) · Italy (1)
Raymond Chung, MD (2) · Raymond T Chung, MD (2) · Ahmed Nasr (1) · Ailsa L Hart, BA(Hons), BM BCh, MRCP, PhD (1) · Alasdair Barr, Ph.D (1) · Allison J McGeer, MD MSc (1) · Andreas Lorenz, MD (1) · Andrew N Milestone, BSc(Hons) MBBS MRCP (1) · Anne Luetkemeyer, MD (1) · Charles Dr Haworth, FRCP (1)
PMID 10950834, PMID 11668104, PMID 12161727, PMID 15949202, PMID 16481828, PMID 17096178, PMID 21908799, PMID 22681960, PMID 22783709, PMID 36625789, PMID 37526194
2009 (2), 2023 (1), 2025 (1), R21DK077678 (1)